BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
Bio Essence Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026
- Market cap
- $21.38M
- P/E (TTM)
- 10.5
- Dividend yield
- –
Bio Essence Corp revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q4 24 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales of goods | – | – | – | – | – | $37.42K | $545.97K | $593.17K | $589.77K | $621.59K | $711.79K | $723.44K | – | – |
| Manufacture service revenue | – | – | – | $563.54K | $521.15K | $282.75K | $409.78K | $398.94K | $430.90K | $364.17K | – | – | – | – |
| Shipping and delivery Income | – | – | $1.22K | $2.13K | $4.99K | $3.77K | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Bio Essence's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.